ReviewMicrobial pathogenesis2013
Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy.
Review in Microbial pathogenesis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Hospitalizations for respiratory syncytial virus (RSV) in Sicily from 2008 to 2021: clinical features and predictors of severity.Italian journal of pediatrics · 2025Article
- Respiratory syncytial virus vaccines for toddlers and school-aged children: a pressing necessity for global health.Frontiers in pediatrics · 2025Article
- The effects of regional climatic condition on the spread of COVID-19 at global scale.The Science of the total environment · 2020Article
- Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice.NPJ vaccines · 2020Article
- Article
- Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.Expert review of vaccines · 2016Review
- Hospitalizations associated with influenza and respiratory syncytial virus among patients attending a network of private hospitals in South Africa, 2007-2012.BMC infectious diseases · 2014Article
- Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.Journal of virology · 2014Article
- Mortality associated with seasonal and pandemic influenza and respiratory syncytial virus among children <5 years of age in a high HIV prevalence setting--South Africa, 1998-2009.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Article
- Inositol-requiring enzyme 1 inhibits respiratory syncytial virus replication.The Journal of biological chemistry · 2014Article
- Rates of respiratory virus-associated hospitalization in children aged <5 years in rural northern India.The Journal of infection · 2014Article
- Pediatric sepsis: important considerations for diagnosing and managing severe infections in infants, children, and adolescents.Virulence · 2014Review
- Epidemiology, etiology, x-ray features, importance of co-infections and clinical features of viral pneumonia in developing countries.Expert review of anti-infective therapy · 2014Review
- Infants and the seasonal influenza vaccine. A global perspective on safety, effectiveness, and alternate forms of protection.Human vaccines & immunotherapeutics · 2014Review
- Unmet needs in respiratory diseases : "You can't know where you are going until you know where you have been"--Anonymous.Clinical reviews in allergy & immunology · 2013Review
- Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease Pathogenesis.Immune network · 2013Review
- A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment.Virology journal · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory viral infections in infants and young children frequently cause illness that can easily progress to hospitalization and death. There are currently no licensed vaccines to prevent respiratory viral disease in children younger than 6 months, reflecting safety concerns and the difficulty in inducing effective immune responses in infants. This review discusses vaccines that have been developed, or are currently being developed, against influenza and respiratory syncytial virus, with a focus on studies performed to demonstrate their safety and efficacy, and the impact of immunologic immaturity and maternal antibodies on the infant response to vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.